ClinicaliQ Trial Snapshot
- Metagenomics for Ocular Inflammation — Recruiting • Rheumatology • NCT06974162.
- What is being tested: Metagenomic sequencing is being evaluated as a diagnostic tool to identify infectious agents in patients with ocular inflammation when standard diagnostic tests have failed to identify a causative organism.
- Patient eligibility overview: The study includes patients presenting with ocular inflammation of unknown or suspected infectious origin where conventional testing methods have not yielded a diagnosis.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The aim of this study is to apply a diagnostic test called 'metagenomic sequencing' to identify the involvement of potential infections in patients with ocular inflammation, where this hasn't been detected by currently available standard testing. For many people with ocular inflammation, no cause is ever found for their disease. In some cases, an infection or infectious trigger is suspected, but currently available tests are inadequate. Metagenomic sequencing can identify almost every globally known infection (bacteria, virus, fungi, parasites) in a sample. Therefore, it has the potential to identify an…
Eligibility Snapshot
- : 1. 18 years of age or older with the capacity to consent 2. Standard of care has not determined a clinical diagnosis 3. Active ocular inflammation with risk of visual loss 4. Clinically suspected infectious or para-infectious cause of ocular inflammation
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.